Previous 10 | Next 10 |
HOOKIPA Pharma shares rise ([[HOOK]] +6.7%) after the company posted fourth-quarter results that beat Wall Street estimates, helped partly by higher cost reimbursements received under the collaboration agreement with Gilead during the quarter.Revenue in the quarter was $5.2M up from...
HOOKIPA Pharma (HOOK): Q4 GAAP EPS of -$0.46 beats by $0.13.Revenue of $5.16M (+42.5% Y/Y) beats by $0.9M.Shares +0.7% PM.Press Release For further details see: HOOKIPA Pharma EPS beats by $0.13, beats on revenue
Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates Follow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Pap...
NEW YORK and VIENNA, Austria, March 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full yea...
Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells 2-vector approach resulted in tumor cures and long-term immunity against tumor rechallenge Publication underscores the...
NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will parti...
NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease/oncology pipeline of six therapeutics. including three in clinical trials including HB-101 f...
NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an...
HOOKIPA Pharma (HOOK) has priced an underwritten public offering of 3.4M common shares at $11.75/share and 2,978 shares of its Series A convertible preferred stock at $11,750/share (each share of Series A preferred stock is convertible into 1,000 shares of common...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com